AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3131068 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group monitored by following PetCO2 and O2 Sat via pulse oximetry
Number of subjects: 40
Study 29411359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie-guided intubation
Number of subjects: 124
Study 29411359 — intervention group
Group type: COMPARATOR
Intervention: Wire-guided intubation
Number of subjects: 124
Study 29411359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 27163253 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched air nitrox (EAN) breathing (36% O2)
Number of subjects: 12
Study 27163253 — intervention group
Group type: COMPARATOR
Intervention: Compressed air breathing
Number of subjects: 12
Study 25637322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 39173
Study 25637322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 39173
Study 25637322 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (various doses)
Number of subjects: 39173
Study 25637322 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol levels
Number of subjects: 39173
Study 22453059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) 50,000 IU, 3 oral capsules every 20 days for two months
Number of subjects: 50
Study 22453059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20693884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-acetaminophen group
Number of subjects: 63
Study 18997143 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans not filling prescription medications
Number of subjects: 399
Study 18997143 — intervention group
Group type: COMPARATOR
Intervention: White patients not filling prescription medications
Number of subjects: 399
Study 18997143 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived income inadequacy among African Americans
Number of subjects: 399
Study 18997143 — intervention group
Group type: COMPARATOR
Intervention: Perceived income inadequacy among white patients
Number of subjects: 399
Study 18997143 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio for African Americans not filling prescriptions
Number of subjects: 399
Study 18997143 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds ratio after adding perceived income inadequacy as a mediator
Number of subjects: 399
Study 16380496 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 16380496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16380496 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 16380496 — intervention group
Group type: EXPERIMENTAL
Intervention: 3' UTR BPI polymorphism
Number of subjects: 0
Study 12791815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration using 10-kDa filters
Number of subjects: 61
Study 12791815 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltration compared with GFR method
Number of subjects: 61
Study 12791815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 61
Study 10977022 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Profile (DSMP)
Number of subjects: 105
Study 8866922 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus flucloxacillin (500 mg four times a day)
Number of subjects: 10
Study 8866922 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (5‐15 mg per week)
Number of subjects: 10
Study 1612904 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 10(6) IU rIFN‐beta per injection
Number of subjects: 10
Study 1612904 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) IU rIFN‐beta per injection
Number of subjects: 10
Study 1612904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral application of rIFN‐beta
Number of subjects: 10
Study 6323783 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug combination (ACNU . VCR, ADM . VCR)
Number of subjects: 47
Study 6323783 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug combination (ACNU . CPA . VCR, ACNU . ADM . VCR)
Number of subjects: 47
Study 6323783 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance Status (PS) 0-1 group
Number of subjects: 47
Study 30764860 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week pulmonary rehabilitation programme
Number of subjects: 60
Study 30764860 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 27233251 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (75 mg administered intravenously 90 seconds after 99mTc-tetrofosmin injection)
Number of subjects: 548
Study 27233251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intravenously 90 seconds after 99mTc-tetrofosmin injection)
Number of subjects: 548
Study 27233251 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (75 mg)
Number of subjects: 548
Study 25890283 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based appointment system with educational content
Number of subjects: 0
Study 25890283 — intervention group
Group type: COMPARATOR
Intervention: Educational content only
Number of subjects: 0
Study 24129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial infliximab treatment
Number of subjects: 229
Study 24129130 — intervention group
Group type: COMPARATOR
Intervention: Delayed infliximab treatment (in arms 1-3)
Number of subjects: 229
Study 24129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discontinuation of infliximab
Number of subjects: 229
Study 24129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting infliximab
Number of subjects: 229
Study 24129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time without infliximab treatment
Number of subjects: 229
Study 24129130 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of infliximab restart
Number of subjects: 229
Study 21104431 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAME intervention (couples' group)
Number of subjects: 173
Study 21104431 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAME intervention (women-only group)
Number of subjects: 173
Study 21104431 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAME intervention (men-only group)
Number of subjects: 173
Study 21104431 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAME intervention
Number of subjects: 173
Study 21104431 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 173
Study 19632961 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented plus functional electrical stimulation (FES) training
Number of subjects: 46
Study 19632961 — intervention group
Group type: COMPARATOR
Intervention: Task-oriented training (control)
Number of subjects: 46
Study 17283346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory CPAP titration
Number of subjects: 68
Study 17283346 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 68
Study 15090768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 229
Study 15090768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 229
Study 15090768 — intervention group
Group type: COMPARATOR
Intervention: No Nevirapine (Control)
Number of subjects: 229
Study 15090768 — intervention group
Group type: COMPARATOR
Intervention: No Hydroxyurea (Control)
Number of subjects: 229
Study 11445632 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (100 mg weekly intramuscular injections)
Number of subjects: 25
Study 11445632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 25
Study 9763809 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 micrograms in NS 10 ml (group C, n 20)
Number of subjects: 40
Study 9763809 — intervention group
Group type: COMPARATOR
Intervention: NS 10 ml as placebo (group P, n 20)
Number of subjects: 40
Study 9763809 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 micrograms
Number of subjects: 40
Study 8143016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Number of subjects: 39
Study 8143016 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 39
Study 3064254 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride (1 tablet per day for 20 days)
Number of subjects: 144
Study 3064254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 3064254 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride
Number of subjects: 144
Study 31965445 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 526
Study 31965445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 31536430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (vibration + noise)
Number of subjects: 138
Study 31536430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (vibration only)
Number of subjects: 138
Study 31536430 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (no exposure)
Number of subjects: 138
Study 31536430 — intervention group
Group type: COMPARATOR
Intervention: Group 1 vs Group 3
Number of subjects: 138
Study 31536430 — intervention group
Group type: COMPARATOR
Intervention: Group 2 vs Group 3
Number of subjects: 138
Study 31536430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 vs Group 2
Number of subjects: 138
Study 28424510 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing training against an inspiratory resistance of 18 cmH2O for 8 weeks
Number of subjects: 20
Study 28424510 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal breathing)
Number of subjects: 20
Study 25361436 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/Cobicistat fixed-dose combination (300/150 mg)
Number of subjects: 64
Study 24090379 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with simvastatin (40 mg/day) and ezetimibe (20 mg/day)
Number of subjects: 100
Study 24090379 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with simvastatin (80 mg/day)
Number of subjects: 100
Study 21355151 — intervention group
Group type: EXPERIMENTAL
Intervention: Du-moxibustion combined with western medicine (herb-partitioned spread moxibustion on the Governor Vessel between Dazhui (GV 14) and Yaoshu (GV 2))
Number of subjects: 210
Study 21355151 — intervention group
Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 210
Study 18469241 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1106
Study 18469241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle group
Number of subjects: 1106
Study 18469241 — intervention group
Group type: COMPARATOR
Intervention: Metformin group
Number of subjects: 1106
Study 17063293 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy and open exploration (including scar revision and neurectomy)
Number of subjects: 24
Study 14563190 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics plus albumin (n = 63)
Number of subjects: 126
Study 14563190 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin treatment (25 g/week)
Number of subjects: 126
Study 14563190 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin treatment
Number of subjects: 126
Study 10852611 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg/day of folic acid (FA), 50.0 mg/day of vitamin B6, 0.4 mg/day of vitamin B12
Number of subjects: 49
Study 10852611 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/day of folic acid (FA) or 17 mg/day of L-5-methyltetrahydrofolate, 50.0 mg/day of vitamin B6, 1.0 mg/day of vitamin B12
Number of subjects: 49
Study 9583629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - subjects could select one product of their choice or were randomly assigned a product during the study weeks.
Number of subjects: 143
Study 8408988 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesis teaching
Number of subjects: 29
Study 8408988 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training
Number of subjects: 29
Study 8408988 — intervention group
Group type: COMPARATOR
Intervention: Control group (problem discussions)
Number of subjects: 29
Study 3776776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study 3776776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30182639 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPT plus anti-oxidant gel formula (propolis)
Number of subjects: 40
Study 30182639 — intervention group
Group type: COMPARATOR
Intervention: NSPT plus chlorhexidine gel formula
Number of subjects: 40
Study 26496015 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg bid
Number of subjects: 0
Study 26496015 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg bid
Number of subjects: 0
Study 26496015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24748465 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + dCIT
Number of subjects: 48
Study 24748465 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 48
Study 24748465 — intervention group
Group type: COMPARATOR
Intervention: CR
Number of subjects: 48
Study 22264742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol hand gel application every 60 minutes (q 60)
Number of subjects: 1437
Study 22264742 — intervention group
Group type: COMPARATOR
Intervention: Alcohol hand gel application every 120 minutes (q 120)
Number of subjects: 1437
Study 22264742 — intervention group
Group type: COMPARATOR
Intervention: Alcohol hand gel application only before lunch (q lunch)
Number of subjects: 1437
Study 22264742 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between q 60 and q 120
Number of subjects: 1437
Study 22264742 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between q 60 and q lunch
Number of subjects: 1437
Study 22264742 — intervention group
Group type: COMPARATOR
Intervention: Comparison between q 120 and q lunch
Number of subjects: 1437
Study 21035620 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific processing condition
Number of subjects: 0
Study 21035620 — intervention group
Group type: COMPARATOR
Intervention: General processing condition
Number of subjects: 0
Study 21035620 — intervention group
Group type: COMPARATOR
Intervention: Control, no-processing condition
Number of subjects: 0
Study 18609155 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES)
Number of subjects: 7
Study 16104443 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 16104443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12461065 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg single dose)
Number of subjects: 0
Study 12461065 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (longer treatment, four days)
Number of subjects: 0
Study 10071289 — intervention group
Group type: EXPERIMENTAL
Intervention: liarozole
Number of subjects: 191
Study 10071289 — intervention group
Group type: COMPARATOR
Intervention: prednisone
Number of subjects: 191
Study 10071289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Scan Index (BSI)
Number of subjects: 191
Study 7572898 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.1 mm tube
Number of subjects: 8
Study 7572898 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8 mm tube
Number of subjects: 8
Study 7572898 — intervention group
Group type: COMPARATOR
Intervention: 2.1 mm tube together with no tube
Number of subjects: 8
Study 2278869 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 84
Study 2278869 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 84
Study 37142 — intervention group
Group type: EXPERIMENTAL
Intervention: Prifinium bromide (90 mg daily before meals)
Number of subjects: 18
Study 37142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30610424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + Macular Grid Photocoagulation (BEV + GRID)
Number of subjects: 32
Study 30610424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 32
Study 30610424 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 32
Study 27838572 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (EX/RP) therapy
Number of subjects: 100
Study 27838572 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 100
Study 27838572 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 100
Study 25809519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) transfusion (12 mL kg(‐1))
Number of subjects: 38
Study 23203904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo-Wii® Bowling (60 min/twice a week for 6 weeks)
Number of subjects: 27
Study 21389739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone injection (IV group)
Number of subjects: 14
Study 21389739 — intervention group
Group type: COMPARATOR
Intervention: Sub-Tenon (ST) posterior triamcinolone injection (ST group)
Number of subjects: 14
Study 19571080 — intervention group
Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 510
Study 19571080 — intervention group
Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 510
Study 18257350 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaformin combined with acupuncture at Baihui (GV 20) and Fengfu (GV 16)
Number of subjects: 100
Study 18257350 — intervention group
Group type: COMPARATOR
Intervention: Diaformin (control group)
Number of subjects: 100
Study 15151523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfluconazole (1000 mg intravenous bolus injection)
Number of subjects: 0
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous push strategy at 40 push min(‐1)
Number of subjects: 12
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency 40
Number of subjects: 12
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency 40 with synchronous strategy
Number of subjects: 12
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Push frequency 70
Number of subjects: 12
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RPE
Number of subjects: 12
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Local RPE
Number of subjects: 12
Study 14504947 — intervention group
Group type: EXPERIMENTAL
Intervention: Central RPE
Number of subjects: 12
Study 10204194 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 7548798 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 19
Study 2265258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% of energy as fat)
Number of subjects: 240
Study 2265258 — intervention group
Group type: COMPARATOR
Intervention: No dietary advice (Control group)
Number of subjects: 240
Study 7467565 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA therapy (chlorambucil, warfarin, dipyridamol, and prednisone)
Number of subjects: 110
Study 7467565 — intervention group
Group type: EXPERIMENTAL
Intervention: CP therapy (imuran and prednisone)
Number of subjects: 110
Study 7467565 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 110
Study 31748227 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5 Gag/Pol and EnvA/B/C (3:1:1:1 mixture)
Number of subjects: 50
Study 31748227 — intervention group
Group type: COMPARATOR
Intervention: rAd5 Gag/Pol
Number of subjects: 50
Study 27612978 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD intervention (early child development intervention)
Number of subjects: 534
Study 27612978 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD intervention
Number of subjects: 534
Study 27612978 — intervention group
Group type: COMPARATOR
Intervention: IHIP intervention (integrated household intervention package)
Number of subjects: 534
Study 25823689 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity running thrice a week for 10 weeks
Number of subjects: 30
Study 25823689 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise prescribed)
Number of subjects: 30
Study 25823689 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity running
Number of subjects: 30
Study 24630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role modeling of fruits at dinner
Number of subjects: 160
Study 24630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role modeling of vegetables at snack
Number of subjects: 160
Study 24630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role modeling of salad at dinner
Number of subjects: 160
Study 24630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental role modeling of fruit at snack
Number of subjects: 160
Study 22999755 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous biliary balloon dilation (PBBD)
Number of subjects: 89
Study 19443354 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg b.d. for four weeks
Number of subjects: 45
Study 19443354 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study 17900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (P‐Max Newtron)
Number of subjects: 290
Study 17900941 — intervention group
Group type: COMPARATOR
Intervention: Bur treatment
Number of subjects: 290
Study 17900941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (P‐Max Newtron) in molars
Number of subjects: 290
Study 17900941 — intervention group
Group type: COMPARATOR
Intervention: Bur treatment in molars
Number of subjects: 290
Study 14980290 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal corticosteroids
Number of subjects: 0
Study 14980290 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroids (early use)
Number of subjects: 0
Study 14980290 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroids
Number of subjects: 0